Rising cases, advanced diagnostics drive biliary tract cancer market growth across 7MM

Increasing cases were driven by aging populations and liver diseases.

The global biliary tract cancer (BTC) market is growing steadily across the seven major markets (7MM)—the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan— driven by rising cases and improved diagnostics, according to DelveInsight Business Research.

In the United States, about 19,000 BTC cases were reported in 2024, with numbers expected to rise by 2034.

Aging populations, chronic liver diseases, parasitic infections, and obesity are key contributors.

Advances in imaging such as MRI, endoscopic ultrasound (EUS), and PET scans are enhancing diagnosis, staging, and treatment planning for cholangiocarcinoma.

FGFR2 inhibitors like pemigatinib and futibatinib are effective in patients with FGFR2 alterations, though resistance due to secondary mutations remains a challenge.

The BTC treatment landscape is also set to expand with emerging drugs.